News

We are thrilled to share that Digistain was hand selected by an expert panel of judges from EIT Health, AstraZeneca Spain, SERMAS and Hospital 12 de […]

We were honoured to recently host Professor Samuel Haryono from the Siloam Group Indonesia during his visit to the Digistain research lab at Imperial College London. […]

We’re thrilled to announce that Digistain® is now available to selected UK private patients, with reimbursement available though Bupa, WPA Health Insurance & Healix. Tim Woodman, Medical […]

We’re proud to share that our clinical validation study, published earlier this year in Breast Cancer Research and Treatment, has been recognised as one of the […]

We are delighted to be in Abu Dhabi this week attending Abu Dhabi Global Healthcare Week with a UK delegation of NHS Organisations and digital health […]

London, UK – 24 January 2024. A clinical validation study of Digistain in 801 patients with ER-positive, HER2-negative early breast cancer (median follow-up 12.7 years) was […]

We are the finalists of Health Tech Challengers 2023. Join us at the event  

Delighted to have been selected by EIT Health as a semi-finalist.